Oral Omega 3 GA. A phase II in subjects with geographic atrophy secondary to AMD 26/03/2013
A phase II, randomized, double masked clinical trial to establish the safety and efficacy of high oral doses of Omega-3 in patients with geographic atrophy secondary to dry age-related macular degeneration.
Key inclusion criteria
Patients with geographic atrophy secondary to dry age-related macular degeneration.
The objectives of this study are to evaluate the safety and efficacy of High-Dose Oral Omega 3 on the Photoreceptors/Retinal Pigment Epithelium/Bruch’s membrane complex in subjects with geographic atrophy secondary to age-related macular degeneration and to evaluate whether improvement in visual function occurs and progression to advanced stages of AMD is delayed.
If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155
Our team of professionals will answer you as soon as possible and we will assess whether you are eligible.
Intravitreal injectionsDry or atrophic AMDExudative or wet AMDRetina scanAutofluorescenceMicroperimetryFluorescein angiographyOptical coherence tomography
Dr. Jordi Monés, M.D., Ph.D.
COMB Medical license number: 22.838
Doctor of Medicine and Surgery
Specialist in Ophthalmology
Specialist in Retina, Macula and Vitreorretinal